Human parainfluenza viruses: Difference between revisions

	Human parainfluenza viruses Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Human parainfluenza viruses from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Human parainfluenza viruses On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Human parainfluenza viruses All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Human parainfluenza viruses
CDC on Human parainfluenza viruses
Human parainfluenza viruses in the news
Blogs on Human parainfluenza viruses
Directions to Hospitals Treating Human parainfluenza viruses
Risk calculators and risk factors for Human parainfluenza viruses

VisualWikitext

Latest revision as of 18:57, 10 August 2015

Transmission electron micrograph of parainfluenza virus. Two intact particles and free filamentous nucleocapsid

For patient information click here.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Human parainfluenza viruses from other Disorders

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Treatment

Medical Therapy | Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1

Template:Jb1 Template:WH Template:WS

@@ Line 2: / Line 2: @@
 [[Image:Parainfluenza virus TEM PHIL 271 lores.jpg|right|thumb|200px|right|Transmission electron micrograph of parainfluenza virus. Two intact particles and free filamentous nucleocapsid]]
 {{Human parainfluenza virus}}
+'''For patient information click [[Human parainfluenza viruses (patient information)|here]].'''
 {{CMG}}
-==Clinical features==
+==[[Human parainfluenza viruses overview|Overview]]==
-Human parainfluenza viruses (HPIVs) are second to respiratory syncytial virus (RSV) as a common cause of lower respiratory tract disease in young children. Similar to RSV, HPIVs can cause repeated infections throughout life, usually manifested by an upper respiratory tract illness (e.g., a cold and/or sore throat). HPIVs can also cause serious lower respiratory tract disease with repeat infection (e.g., pneumonia, bronchitis, and bronchiolitis), especially among the elderly, and among patients with compromised immune systems.
-==The viruses==
-HPIVs are negative-sense, single-stranded RNA viruses that possess fusion and hemagglutinin-neuraminidase glycoprotein "spikes" on their surface. There are four serotypes types of HPIV (1 through 4) and two subtypes (4a and 4b). The virion varies in size (average diameter between 150 and 300 nm) and shape, is unstable in the environment (surviving a few hours on environmental surfaces), and is readily inactivated with soap and water.
-===Types===
-The four serotypes include:
-* Human parainfluenza virus type 1: HPIV-1 (most common cause of [[croup]]; also other upper and lower respiratory tract illnesses typical)
+==[[Human parainfluenza viruses historical perspective|Historical Perspective]]==
-* Human parainfluenza virus type 2: HPIV-2 (causes croup and other upper and lower respiratory tract illnesses)
+==[[Human parainfluenza viruses classification|Classification]]==
-* Human parainfluenza virus type 3: HPIV-3 (associated with [[bronchiolitis]] and [[pneumonia]])
+==[[Human parainfluenza viruses pathophysiology|Pathophysiology]]==
-* Human parainfluenza virus type 4: HPIV-4 (includes subtypes 4a and 4b)
+==[[Human parainfluenza viruses causes|Causes]]==
-==Diagnosis==
+==[[Human parainfluenza viruses differential diagnosis|Differentiating Human parainfluenza viruses from other Disorders]]==
-Infection with HPIVs can be confirmed in two ways: 1) by isolation and identification of the virus in cell culture or by direct detection of the virus in respiratory secretions (usually, collected within one week of onset of symptoms) using immunofluorescence, enzyme immunoassay, or polymerase chin reaction assay, and 2) by demonstration of a significant rise in specific IgG antibodies between appropriately collected paired serum specimens or specific IgM antibodies in a single serum specimen.
+==[[Human parainfluenza viruses epidemiology and demographics|Epidemiology and Demographics]]==
+==[[Human parainfluenza viruses risk factors|Risk Factors]]==
+==[[Human parainfluenza viruses natural history, complications and prognosis|Natural History, Complications and Prognosis]]==
-==Prevention==
+==Diagnosis==
+[[Human parainfluenza viruses history and symptoms|History and Symptoms]] | [[Human parainfluenza viruses physical examination|Physical Examination]] | [[Human parainfluenza viruses laboratory findings|Laboratory Findings]] | [[Human parainfluenza viruses chest x ray|Chest X Ray]] | [[Human parainfluenza viruses other imaging findings|Other Imaging Findings]] | [[Human parainfluenza viruses other diagnostic studies|Other Diagnostic Studies]]
-No vaccine is currently available to protect against infection caused by any of the HPIVs; however, researchers are developing vaccines against HPIV-1 and -3 infections. Passively acquired maternal antibodies may play a role in protection from HPIV types 1 and 2 in the first few months of life, highlighting the importance of breast-feeding. Strict attention to infection-control practices should decrease or prevent spread of infection. Frequent handwashing and not sharing items such as cups, glasses, and utensils with an infected person should decrease the spread of virus to others. Excluding children with colds or other respiratory illnesses (without fever) who are well enough to attend child care or school settings will probably not decrease the spread of HPIVs, because the viruses are often spread in the early stages of illness. In a hospital setting, spread of HPIVs can and should be prevented by strict attention to contact precautions, such as handwashing and wearing of protective gowns and gloves.
-==References==
-* American Academy of Pediatrics. Parainfluenza Viral Infections. In: Peter G, ed. 1997 Red Book: Report of the Committee on Infectious Diseases. 24th ed. Elk Grove Village, IL: American Academy of Pediatrics; 1997: 379.
-* Collins PL, Chanock RM, McIntosh K. Parainfluenza viruses. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. 3rd ed. Philadelphia: Lippincott-Raven; 1995: 1205-41.
-* Glezen WP, Denny FW. Parainfluenza Viruses In: Evans A, Kaslow R, eds. Viral Infections in Humans: epidemiology and control. 4th ed. New York: Plenum; 1997:551-67.
+==Treatment==
+[[Human parainfluenza viruses medical therapy|Medical Therapy]] | [[Human parainfluenza viruses prevention|Prevention]] | [[Human parainfluenza viruses cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Human parainfluenza viruses future or investigational therapies|Future or Investigational Therapies]]
+==Case Studies==
+[[Human parainfluenza viruses case study one|Case #1]]
 [[Category:Pulmonology]]
 [[Category:Viruses]]
-[[de:Parainfluenza]]
-[[fr:Parainfluenza]]
-[[pl:Wirus paragrypy]]
 {{jb1}}
 {{WH}}
 {{WS}}

Human parainfluenza viruses: Difference between revisions

Latest revision as of 18:57, 10 August 2015

Diagnosis

Treatment

Case Studies

Navigation menu